Milestone Scientific Inc. (MLSS) is a leading
medical research and development company
that designs and patents innovative injection
technology. Milestone's computer controlled
systems make injections precise, efficient, and
virtually painless.
With 174 foreign patents and 19 US patents
issued Milestone Scientific is the leader in
modern injection technology.
The external healthcare environment is changing rapidly and providers are under increasing pressure to innovate with increasing speed and efficiency.
Be it experimenting with new care delivery models to improve care coordination, redesigning workflows to enhance efficiency, or developing new products that improve clinical outcomes, hospitals and their service lines are looking for effective ways to harness the creative power of physicians and employees to solve problems that matter. However, few organizations innovate in an orderly, reliable way.
Great ideas remain captive in the heads of physicians and employees and one-off attempts to spur innovation through “hack-a-thons” and “pitch days” prove disappointing. As an academic medical center and a world leader in orthopedics, Hospital for Special Surgery has a long history of results-oriented innovation.
In this webinar, we will share:
– HSS’ systematic approach for driving innovation
– strategies for generating new insights and developing novel solutions
– processes for piloting and testing new ideas
– guiding principles for creating a culture of innovation
– advice on how to build your very own innovation infrastructure
About the Speaker:
Mark Angelo is Vice President, Innovation & Business Development for Hospital for Special Surgery. Mark joined HSS in 2009 and has held various senior management positions at the Hospital across operations, strategy and business development. As Vice President, Innovation & Business Development, Mark is responsible for advancing hospital strategic priorities related to quality and efficiency, innovation, growth and diversification. One of his key responsibilities includes leading the Operational Excellence program, a hospital-wide initiative that leverages industrial engineering principles to maximize quality and efficiency. Mark also leads the HSS Innovation Center whose mission is to support the development and commercialization of early-stage technologies and solutions.
Prior to joining HSS, Mark worked as a management consultant for Monitor Group where he specialized in operations strategy and organizational design. Mark holds a Bachelor of Applied Science in Biomedical Engineering from the University of Toronto and a Master of Business Administration from Harvard Business School.
Milestone Scientific Inc. (MLSS) is a leading
medical research and development company
that designs and patents innovative injection
technology. Milestone's computer controlled
systems make injections precise, efficient, and
virtually painless.
With 174 foreign patents and 19 US patents
issued Milestone Scientific is the leader in
modern injection technology.
The external healthcare environment is changing rapidly and providers are under increasing pressure to innovate with increasing speed and efficiency.
Be it experimenting with new care delivery models to improve care coordination, redesigning workflows to enhance efficiency, or developing new products that improve clinical outcomes, hospitals and their service lines are looking for effective ways to harness the creative power of physicians and employees to solve problems that matter. However, few organizations innovate in an orderly, reliable way.
Great ideas remain captive in the heads of physicians and employees and one-off attempts to spur innovation through “hack-a-thons” and “pitch days” prove disappointing. As an academic medical center and a world leader in orthopedics, Hospital for Special Surgery has a long history of results-oriented innovation.
In this webinar, we will share:
– HSS’ systematic approach for driving innovation
– strategies for generating new insights and developing novel solutions
– processes for piloting and testing new ideas
– guiding principles for creating a culture of innovation
– advice on how to build your very own innovation infrastructure
About the Speaker:
Mark Angelo is Vice President, Innovation & Business Development for Hospital for Special Surgery. Mark joined HSS in 2009 and has held various senior management positions at the Hospital across operations, strategy and business development. As Vice President, Innovation & Business Development, Mark is responsible for advancing hospital strategic priorities related to quality and efficiency, innovation, growth and diversification. One of his key responsibilities includes leading the Operational Excellence program, a hospital-wide initiative that leverages industrial engineering principles to maximize quality and efficiency. Mark also leads the HSS Innovation Center whose mission is to support the development and commercialization of early-stage technologies and solutions.
Prior to joining HSS, Mark worked as a management consultant for Monitor Group where he specialized in operations strategy and organizational design. Mark holds a Bachelor of Applied Science in Biomedical Engineering from the University of Toronto and a Master of Business Administration from Harvard Business School.
Milestone Scientific Inc. (MLSS) is a leading
medical research and development company
that designs and patents innovative injection
technology. Milestone's computer controlled
systems make injections precise, efficient, and
virtually painless.
With 174 foreign patents and 19 US patents
issued Milestone Scientific is the leader in
modern injection technology.
ClinActis Pte Ltd is a full service CRO providing clinical trial services to the pharmaceutical, medical device, medical nutrition and biotech companies in Asia Pacific. Established in 2009, ClinActis Pte Ltd is headquartered in Singapore.
ClinActis Experience
• 45 years experience in clinical research in pharmaceutical and biotechnology companies as well as CROs
• 27 years experience in Asia Pacific, including Australia/New Zealand, China, Malaysia, Hong Kong, India, Indonesia, The Philippines, Singapore, South Korea, Taiwan, Thailand and Japan
• Extensive knowledge of regulatory frameworks, best KOLs and sites across the region
• Vast therapeutic experience including Cardiovascular, CNS, Endocrinology, Infectious diseases, Oncology, and Respiratory
Workshop de Inovação em Medical Devices, realizado pelo EmpreenderSaúde com os professores de Stanford Robson Capasso e Ravi Pamnani.
Um workshop de um dia inteiro sobre como criar novos equipamentos médicos com a técnica (adaptada à realidade brasileira) que Stanford utiliza todos os anos para treinar médicos, engenheiros e empreendedores com o apoio de empresas como Medtronic, Covidien, Abbott, Johnson&Johnson entre outros.
Immuron Ltd (NASDAQ: IMRN) is an Australian biopharmaceutical company focused on immunotherapy using dairy-derived antibody products for humans. Immuron has a unique and versatile technology platform that is capable of generating a wide range of products, all with a high safety profile. The versatility of Immuron’s platform technology enables the development of medicines that target a large range of medical needs, including infectious diseases, immune mediated disorders, and cancers. The versatility is also a function of the dairy origin of Immuron’s antibodies, which enables Immuron to commercialize its platform derived products through a range of regulatory pathways, including prescription (Rx), medical foods, over-the-counter (OTC) medicines, and dietary supplements. The Company has received clearance from the FDA to commence a Phase IIb clinical trial for its NASH product (IMM-124E), a potential blockbuster, in less than three years from commencing its NASH R&D program. Additionally, Immuron has one marketed product (Travelan, for the prevention of travelers’ diarrhea) and a pipeline of products at various stages of clinical and earlier development. Visit RedChip.com for more information.
Lifecare is the country's premier full-service diagnostic center with laboratory, providing expertise in imaging and digital pathology services. Our integrated diagnostic services help doctors personalize patient care to optimally treat disease and maintain health and wellness. We are committed to providing only the highest level of testing quality and service and working with you to provide unique solutions to your most challenging needs. http://www.lifecareindia.com/
Milestone Scientific Inc. (MLSS) is a leading
medical research and development company
that designs and patents innovative injection
technology. Milestone's computer controlled
systems make injections precise, efficient, and
virtually painless.
With 174 foreign patents and 19 US patents
issued Milestone Scientific is the leader in
modern injection technology.
ClinActis Pte Ltd is a full service CRO providing clinical trial services to the pharmaceutical, medical device, medical nutrition and biotech companies in Asia Pacific. Established in 2009, ClinActis Pte Ltd is headquartered in Singapore.
ClinActis Experience
• 45 years experience in clinical research in pharmaceutical and biotechnology companies as well as CROs
• 27 years experience in Asia Pacific, including Australia/New Zealand, China, Malaysia, Hong Kong, India, Indonesia, The Philippines, Singapore, South Korea, Taiwan, Thailand and Japan
• Extensive knowledge of regulatory frameworks, best KOLs and sites across the region
• Vast therapeutic experience including Cardiovascular, CNS, Endocrinology, Infectious diseases, Oncology, and Respiratory
Workshop de Inovação em Medical Devices, realizado pelo EmpreenderSaúde com os professores de Stanford Robson Capasso e Ravi Pamnani.
Um workshop de um dia inteiro sobre como criar novos equipamentos médicos com a técnica (adaptada à realidade brasileira) que Stanford utiliza todos os anos para treinar médicos, engenheiros e empreendedores com o apoio de empresas como Medtronic, Covidien, Abbott, Johnson&Johnson entre outros.
Immuron Ltd (NASDAQ: IMRN) is an Australian biopharmaceutical company focused on immunotherapy using dairy-derived antibody products for humans. Immuron has a unique and versatile technology platform that is capable of generating a wide range of products, all with a high safety profile. The versatility of Immuron’s platform technology enables the development of medicines that target a large range of medical needs, including infectious diseases, immune mediated disorders, and cancers. The versatility is also a function of the dairy origin of Immuron’s antibodies, which enables Immuron to commercialize its platform derived products through a range of regulatory pathways, including prescription (Rx), medical foods, over-the-counter (OTC) medicines, and dietary supplements. The Company has received clearance from the FDA to commence a Phase IIb clinical trial for its NASH product (IMM-124E), a potential blockbuster, in less than three years from commencing its NASH R&D program. Additionally, Immuron has one marketed product (Travelan, for the prevention of travelers’ diarrhea) and a pipeline of products at various stages of clinical and earlier development. Visit RedChip.com for more information.
Lifecare is the country's premier full-service diagnostic center with laboratory, providing expertise in imaging and digital pathology services. Our integrated diagnostic services help doctors personalize patient care to optimally treat disease and maintain health and wellness. We are committed to providing only the highest level of testing quality and service and working with you to provide unique solutions to your most challenging needs. http://www.lifecareindia.com/
Versiunea digitala a celei de-a cincea editii a ghidului Public Relations Report, o publicatie anuala dedicata comunitatii de relatii publice din Romania, realizata de Evensys pentru PR Forum 2012. Ghidul include lista agentiilor de
relatii publice importante de pe piata locala, agentii de monitorizare si consultanti online.
10 Most Innovative CRO’s To Watch In 2022.pdfinsightscare
During the COVID-19 pandemic, if clinicians, healthcare service-providing staff, nurses, and doctors were battling at the forefront, then the Clinical Research Organizations (CROs) have been working hard
Europe's Top 5 Effective Leaders in Healthcare Edition.pdfinsightscare
Insights Care’s team carried out its own research and found the ‘Europe's Top 5 Effective Leaders in Healthcare,’ and depicted their revolutionary tales
DevicePharm is an Irvine, California-based provider of marketing strategy and integrated marketing communications solutions for organizations serving medical professionals and healthcare consumers. As the name suggests, our clients are medical device and pharmaceutical companies along with biotech and life sciences firms ranging from investor-backed startups to established market leaders with over $30 billion in annual revenue.
Because we are focused, we understand the specific and dynamic nature of marketing medical devices, the complexities of research-useヨonly products, and the constant change in AdvaMed, PhRma, and FDA regulations. Our knowledge of these markets provides our clients with the expertise and rapid response required to strengthen their position and exceed their goals.
This distinct focus is what helps us deliver outstanding results for our clients.
The DevicePharm team of marketing, creative, multimedia, and medical professionals provides clients with award-winning professional advertising and direct marketing, practitioner and consumer-focused web and e-media design, comprehensive medical education, and
direct-to-consumer and physician-to-consumer programs. In addition, we have demonstrated success in creating new markets by generating physician and consumer demand for emerging and elective medical procedures.
Medical device, biotech, life sciences, and pharmaceutical marketers turn to our experienced and talented team to help them be more competitive and identify opportunities to achieve success.
1. JOHN P. HICKEY
3339 Cottonfield Dr. 843-532-9462
Mt. Pleasant, SC 29466 jp1hickey@comcast.net
SUMMARY
An award winning, committed and passionate individual with twenty years of proven success in the
medical device industry. A broad experience including both large and emerging technology companies
in the areas of IDE study recruitment, market development, global sales, management, training,
marketing, and product development. Strengths include excellent communication skills, personnel
management and development of key opinion leaders with adoption of new technology. Areas of
experience include Cardiology, Radiology, General & Vascular Surgery, Gastrointestinal Endoscopy,
and Interventional Bronchoscopy.
CAREER HISTORY
PULMONX CORPORATION, REDWOOD CITY, CA SEPTEMBER 2014 – PRESENT
Pulmonx is a privately-held (OUS) commercial stage medical device company focused on
developing both diagnostic and therapeutic technologies for Interventional Pulmonology. Pulmonx
has developed the Endobronchial Valve (EBV) Therapy, a non-surgical approach to treating
emphysema that uses the Chartis Pulmonary Assessment System to optimize the placement of a
series of unique self-expanding valves. In the United States, Pulmonx is conducting the LIBERATE
Clinical Study to evaluate the safety and effectiveness of the Zephyr valve in patients with severe
emphysema.
Director of Market Development
Responsible for driving patient enrollment in US IDE study sites thru social media, print media,
patient advocacy organizations, TV news stories, and physician referral networks.
Achieved and/or exceeded individual quarterly patient enrollment quotas.
Identify and develop relationships with key institutions and thought leading physicians.
Experienced in training physicians on the proper use of Pulmonx’s products, and assisting them
as appropriate during the clinical study.
Work with other functional groups in the company to support regulatory, clinical, and
development activities.
BRONCUS MEDICAL/TECHNOLOGIES INC., MOUNTAIN VIEW, CA MAY 2009 – SEPTEMBER 2014
A venture capital funded medical device company focused on providing a portfolio approach of
devices related to Interventional Pulmonology/Thoracic Surgery. Current development includes
investigation of a novel minimally-invasive treatment option (airway bypass/drug eluding stents) for
patients with emphysema. The organization has US commercial approval to launch imaging
technology (virtual bronchoscopic navigation), tissue sampling and mini-Doppler ultrasound for
diagnosis of lung disease.
Director, Global Sales and Market Development (March 2012 – September 2014)
Established a team of 4 regional sales managers and 2 marketing managers to focus on
achievement of commercialization objectives across the US.
Identify and develop key strategic institutions/physicians for reference centers.
Responsible for product launches in international markets recognizing CE mark approval by
conducting market analysis, developing revenue models, and establishing product champions.
Identify, train, and manage international distributors to sell in Europe, Asia and South America,
while providing physician proctoring and case coverage.
Assist with development of marketing and training materials for physicians and distributors.
Assist with reimbursement strategy/activities in all markets.
2. Southeast Region Sales Manager (May 2009 - March 2012)
Responsible for the market development of 2 new medical technologies that provide 3D virtual
bronchoscopic procedure planning and navigation, and a diagnostic biopsy device for lung
disease.
Assist Global V.P. of Sales in building a direct sales force for US launch of 3 products in 2010.
Consistently finished #1 in US sales amongst 4 Regions since launch with 12 navigation
systems sold to date.
Identified market opportunity to separate and expand the company’s platform product into the
radiology market.
Promoted to Director, Sales & Market Development in March 2012.
ALVEOLUS INC., CHARLOTTE, NC FEBRUARY 2008 - APRIL 2009
A venture capital funded medical device company with removable nitinol-silicone (hybrid) stents.
These hybrid stents are indicated for tracheobronchial, esophageal, duodenal, biliary, and colonic
applications. The company was acquired in March of 2009 by Merit Medical Systems, Inc. (Nasdaq:
MMSI) a worldwide designer, developer, manufacturer and marketer of medical devices used in
interventional and diagnostic procedures.
Co-Principal, Key Account Sales Manager
Responsible for educating, training, and selling to Thoracic Surgeons, Interventional
Pulmonologists, Gastroenterologists, Bariatric Surgeons, and Surgical Oncologists who utilize
non-vascular stents for obstructive disease and leaks in the tracheobronchial, esophageal, and
biliary anatomy. My area of responsibility included Florida, Georgia, North and South Carolina.
Experienced in identifying and implementing new device designs for stents, and delivery
systems with engineers, and key opinion leading physicians.
Created business development and marketing programs that include physician education
outreach programs, product training and demonstration tools, and patient education literature.
Responsible for managing and mentoring the NC Sales Associate.
Ranked 2 out of 14 Sales Managers, 2008.
Regained business at 11 dormant accounts, established 8 new accounts, and increased business
at 11 current accounts since hiring.
GUIDANT/ABBOTT VASCULAR, SANTA CLARA, CA APRIL 2004 - SEPTEMBER 2007
Guidant’s Endovascular Division developed the first US commercially available carotid artery stent
and embolic protection device system for use by Cardiologists, Radiologists and Vascular Surgeons.
The company was acquired by Abbott Laboratories in 2006 to create the cornerstone for Abbott
Vascular, an international market leader in the areas of drug eluting coronary stent platforms,
rapid exchange technology, balloon dilatation catheters and guide wires.
Senior Territory Manager
Responsible for selling carotid stents, embolic protection devices, peripheral balloon dilators,
guidewires, and biliary stents to Interventional Radiologists, Neuro-Radiologists, Neuro-
Surgeons, Thoracic Surgeons, Vascular Surgeons, and Interventional Cardiologists.
Increased territory revenue more than 242% and $1,000,000 in 2005.
Individually trained 31 physicians on the use of the Acculink/Xact carotid stent systems, and
assisted 10 hospitals with the CMS credentialing for carotid artery stenting.
Increased territory revenue more than 55% and $387,653 in 2004.
Experienced in implementing economic programs that reduce cost and increase
revenue for both hospitals and physicians.
Consistently exceeded sales plan: 108% 2004, 109% 2005, 105% 2006.
Ranked 7 out of 110 Territory Managers, 117% to sales plan Q3 2007.
Promoted to Senior Territory Manager in March, 2006.
3. BOSTON SCIENTIFIC, ENDOSCOPY DIVISION, NATICK, MA OCTOBER 1997 - APRIL 2004
Boston Scientifics’ Endoscopy Division is worldwide leader in developing and commercializing
technologies for diagnosing and treating diseases of the digestive system, airway and lungs.
Sales Trainer (May 2000 to April 2004)
Responsible for training new territory managers on the clinical aspects and selling strategies for
stents, biliary, dilation, hemostasis, polypectomy, tissue biopsy, GERD, and enteral feeding
devices.
Selected to ENTERYX Market Research Team 2001.
Individually trained 11 new territory managers.
Experienced in creating and presenting selling/training programs for the US sales force.
Increased new product sales by 58% & $234,775 in 2003.
Increased territory revenue more than $155,000 in 2002.
Received REGION OF THE YEAR AWARD in 2002 and 1997.
Territory Manager (October 1997 to May 2000)
Responsible for selling a variety of endo-prosthetic stents, diagnostic, and therapeutic
endoscopic instruments to Gastroenterologists, General Surgeons, Thoracic Surgeons, ENT
Surgeons, Colo-rectal Surgeons, Pulmonologists, and Radiologists.
Experienced in conducting accredited continuing education courses for physicians, nurses, and
techs.
Selected to the SALES SUCCESS MODEL TEAM 12/99. Increased new products sales more than
$107,000 in 1999.
Received EAGLE AWARD for outstanding product focus results and leadership 2/00.
Increased territory revenue more than $205,000 in 2000.
Promoted to SALES TRAINER 5/00.
United States Surgical Corporation, Norwalk, CT APRIL 1996 – October 1997
US Surgical was a worldwide leading innovator of surgical staplers, suture, clips and laparoscopic
devices. The company was acquired by Tyco Inc. in 1997 and it eventually was purchased by
Covidien.
Wound Closure Technician
Responsible for selling surgical staplers, clips, suture, laparoscopic devices, cardiovascular
instruments, stereo-tactic imaging systems, and lymphatic mapping devices to hospitals and
clinics.
Consistently achieved and exceeded new product sales quotas.
Increased territory revenue more than 53% & $700,000 in 1997.
Received the TOP GUN SALES AWARD 9/97 and 6/97.
Experienced in clinically training surgeons, nurses, and surgical scrub techs in the use of U.S.
Surgical instruments.
Experienced in negotiating pricing contracts with hospital administrators and implementing
client partnering programs.
Astra Pharmaceuticals, RX Division, Westborough, MA February 1995 – April 1996
Astra AB was a publically traded Swedish company that developed a variety of drugs for
cardiovascular, GERD, allergy, pain, and lung diseases. Astra has since merged with Merck and
Zuniga.
Sales Representative
Responsible for selling Rhinocort (Budesonide), an anti-inflammatory glucocorticoid steroid for
the treatment of rhinitis. Targeted physicians were ENT Surgeons, Allergists, Internal Medicine,
and Primary Care.
Responsible for selling Toprol XL (Metoprolol Succinate), a Beta 1 selective blocking agent for
the treatment of angina and hypertension. Targeted physicians were Cardiologists,
Cardiothoracic Surgeons, and Primary Care.
Selected to speak on the Cycle III Sales Training Audiotape.
4. EDUCATION/OTHER RELATED EXPERIENCE
Wright State University, Dayton, OH 1990
Bachelor of Arts, ECONOMICS
4 years experience as an Account Executive for Banner Enterprises in Charleston, SC. I was
responsible for selling protective equipment and clothing to police departments, fire
departments, emergency medical services, and industrial facilities. (1991-1995)